Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a report released on Saturday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Stock Performance

Shares of NASDAQ CYCC opened at $0.30 on Friday. The business’s 50 day moving average price is $0.35 and its 200-day moving average price is $0.57. Cyclacel Pharmaceuticals has a fifty-two week low of $0.29 and a fifty-two week high of $4.00. The company has a market cap of $1.87 million, a price-to-earnings ratio of -0.03 and a beta of 0.28.

Insider Transactions at Cyclacel Pharmaceuticals

In related news, CEO David E. Lazar sold 194,628,820 shares of the stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $0.03, for a total value of $5,838,864.60. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 23.97% of the company’s stock.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.